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Abstract: Polyamines are multivalent organic cations essential for many cellular functions,
including cell growth, differentiation, and proliferation. However, elevated polyamine levels
are associated with a slew of pathological conditions, including multiple cancers.
Intracellular polyamine levels are primarily controlled by the autoregulatory circuit compris
ing two different protein types, Antizymes (OAZ) and Antizyme Inhibitors (AZIN), which
regulate the activity of the polyamine biosynthetic enzyme ornithine decarboxylase (ODC).
While OAZ functions to decrease the intracellular polyamine levels by inhibiting ODC
activity and exerting a negative control of polyamine uptake, AZIN operates to increase
intracellular polyamine levels by binding and sequestering OAZ to relieve ODC inhibition
and to increase polyamine uptake. Interestingly, OAZ and AZIN exhibit autoregulatory
functions on polyamine independent pathways as well. A growing body of evidence demon
strates the dysregulation of AZIN expression in multiple cancers. Additionally, RNA editing
of the Azin1 transcript results in a “gain-of-function” phenotype, which is shown to drive
aggressive tumor types. This review will discuss the recent advances in AZIN’s role in
cancers via aberrant polyamine upregulation and its polyamine-independent protein regula
tion. This report will also highlight AZIN interaction with proteins outside the polyamine
biosynthetic pathway and its potential implication to cancer pathogenesis. Finally, this
review will reveal the protein interaction network of AZIN isoforms by analyzing three
different interactome databases.
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Reprogramming of the metabolic landscape is a hallmark of cancer cells.1 Transformed
cells modulate metabolic pathways and nutrient uptake using various adaptation
mechanisms to support tumor progression.2 In this regard, the polyamine metabolism
is a central pathway hijacked by cancer cells.3,4 Polyamines are small aliphatic poly
cations biosynthesized from amino acids such as methionine and ornithine and are
tightly regulated by de novo synthesis and diet.5 Polyamines play a crucial role in key
cellular processes such as cell growth, cell proliferation, apoptosis, and gene
regulation.6,7 Notably, polyamine levels are frequently dysregulated in multiple cancer
types.3,4 Besides malignant transformation, elevated polyamines are essential for the
developmental and compensatory growth of cancer cells in response to systemic
stimuli like hormones.8 Elevated polyamine levels contribute to cancer progression
by binding to nucleic acids, thereby controlling DNA replication, transcription,
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translation, and cell cycle progression.9–12 Dysregulation of
polyamine metabolism is directly controlled by oncogenic
signaling pathways, including RAS, PI3K, mTORC, and
MYC genes.13 Specifically, MYC oncogenes upregulate the
expression of ornithine decarboxylase (ODC), a pyridoxal
phosphate-dependent enzyme. ODC converts ornithine to
putrescene, which is the first rate-limiting step in polyamine
biosynthesis.14 Putrescine is an important polyamine that is
further converted to the other two polyamines, spermidine
and spermine in cells (Figure 1). Spermidine is further
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utilized for the post-translational modification of a lysine
residue on the eukaryotic initiation factor 5A isoform 1
(eIF5A).15 This process, termed as hypusination, is essential
for eIF5A to influence neoplastic transformation.16
ODC is catalytically active as a homodimer, and its
expression is tightly regulated.17 The monomeric form of
ODC is short-lived and gets degraded by the proteasome
machinery.18 Notably, ODC levels are elevated at low and
repressed at high polyamine levels, respectively. The posttranslational regulation of ODC is mediated by two different

Figure 1 Dysregulated polyamine pathway in cancers. The red arrows indicate established pathways that lead to cancer metastasis and progression. Dotted red arrows
indicate the recently discovered role of AZINs (AZIN1 to be specific) in cancer progression. A putative AZIN1-interaction with proteins from other pathways is shown, the
dysregulation of which leads to multiple cancers. RNA edited mutant form of AZIN1 can also lead to cancers. The blue arrows indicate the tumor suppressor function of
OAZ (OAZ1 to be specific). The black arrows indicate a normal pathway.
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antagonistic protein isoforms, Ornithine Decarboxylase
Antizymes (OAZs) and Antizyme Inhibitors (AZINs). OAZ
targets ODC for proteasomal degradation via ubiquitin inde
pendent pathways.19 Specifically, OAZ binds the carboxylic
end of monomeric ODC and presents it to the 26S protea
some, thereby decreasing the half-life of ODC to minutes.18
Interestingly, ODC is stabilized by its non-catalytic homolog
AZIN, which forms a tighter complex with OAZ, thereby
disrupting ODC-OAZ interaction. This rescues ODC activity
resulting in increased polyamine synthesis.18
Polyamines regulate the expression of functional OAZ
at the transcriptional level. OAZ is encoded by two open
reading frames ORF1 and ORF2. The ORF1 with
a premature stop codon leads to the expression of
a truncated OAZ, which lacks the ability to target ODC
for proteasomal degradation. Interestingly, high polyamine
levels manipulate the ribosome to switch to a +1 reading
frame, which then reads ORF2 and skips the premature
stop codon in ORF1. This results in the expression of
functional OAZ.20,21 Four different isoforms of antizymes
have been reported in mammals – OAZ1, OAZ2, OAZ3,
and OAZ4.22,23 OAZ1 is commonly found in almost all
tissues and functions to inhibit and degrade ODC. OAZ2 is
functionally similar to OAZ1 and can inhibit ODC and
target it for proteasomal degradation. OAZ3 is specific to
the testis and is restricted to the late stage of sperm
production. The putative fourth member OAZ4 isolated
from the human brain has been demonstrated to bind to
ODC, but the ability to promote ODC degradation has not
yet been examined.24–30 In addition to modulating ODC
activity, OAZ also regulates polyamine levels by inhibiting
polyamine transport.31–33 However, the regulatory
mechanism of OAZ-mediated polyamine transport is not
clear.
AZINs play a pivotal role in polyamine homeostasis by
modulating OAZ activity. Two isoforms of antizyme inhi
bitors are reported - AZIN1 and AZIN2. Both isoforms can
affect intracellular polyamine levels by binding to OAZ
isoforms, thereby rescuing ODC activity.34,35 Notably,
AZINs can also increase the uptake of extracellular poly
amines, likely by binding to and sequestering OAZ, thereby
preventing the negative regulation of polyamine transport
by OAZ.36 AZIN’s role in mammalian pathophysiology is
slowly emerging as researchers focus on understanding its
function outside the polyamine biosynthetic pathway.
Moreover, both AZIN1 and AZIN2 have been implicated
in a variety of mammalian disease . Notable research
advancements involve understanding the role of AZIN1 in
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promoting multiple cancers. The current review focuses on
structural and functional aspects of AZIN isoforms in poly
amine dependent and independent processes. Furthermore,
it also highlights the contribution of AZIN isoforms in
human cancers.

Regulation of Antizyme Inhibitors
AZIN1 Cellular Distribution and
Regulation
AZIN1 is ubiquitously expressed in all proliferating cell
types, as evidenced by its mRNA levels.37,38 AZIN1
mRNA in mice is reported to undergo alternative splicing
to generate multiple forms of Azin1 transcripts.39 AZIN1
expression is regulated by various factors, including nutri
tional stimuli and other growth factors.40 Moreover,
increased polyamine levels can affect Azin1 transcription
and splicing patterns.39 Cellular AZIN1 levels is also con
trolled by its proteasomal degradation. Unlike ODC,
AZIN1 is degraded by the proteasome machinery via the
ubiquitin-dependent pathway.41 Notably, AZIN1 is stabi
lized by its interaction with OAZ1, likely by interfering
with the ubiquitin-mediated degradation.29,42

AZIN2 Cellular Distribution and
Regulation
AZIN2 is primarily expressed in the testis and brain.
Because of its tissue-specific distribution, AZIN2 is
thought to play a major role in terminal differentiation.43
As a short-lived protein, AZIN2 has a lower half-life than
ODC but is interestingly more stable than AZIN1.43,44
Like AZIN1, its interaction with OAZ isoforms increases
the stability of AZIN2. Furthermore, cellular studies indi
cate that while AZIN2 is primarily degraded via the pro
teasomal pathway, it may undergo degradation via
alternative mechanisms as well.44

Structural and Functional Features
of Antizyme Inhibitors
Structural Features of AZIN1 Interaction
with OAZ1
Originally discovered in rat liver extracts as an antizyme
scavenger, AZIN1 was thought to be an ODC derivative due
to the similarities in protein sequences.40,45,46 While it shares
a 49% sequence identity with ODC, AZIN1 lacks ornithine
decarboxylating activity. Besides, AZIN1 is 41% structurally
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at two different sites, site-A, and site-B, as seen from a cocrystal structure of OAZ1 bound to AZIN1 (Figure 2).48
Site-B in AZIN1 includes the following residues – S91,
K92, N93, C114, Q116, V117, S118, Q119, D134, N135,
E136, I137, E138, K140, R144. These residues in AZIN1
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identical to Gm853, an ODC homolog in mice. Interestingly,
Gm853 exhibits the function of both AZIN1 and ODC.47
Structural studies indicate that the binding mode of
AZIN-OAZ1 interaction is similar to ODC-OAZ1
interaction.48 OAZ1 interacts with AZIN1 predominantly
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Figure 2 Structural features of AZIN1-OAZ1 interaction. A crystal structure of the AZIN1-OAZ1 complex (PDB ID: 4zgz) is shown in the figure. (A) AZIN1 is shown as
grey colored ribbons with site A shaded in blue and site B in pink. OAZ1 is shown in gold with the helix H1 and the adjoining loop shown in blue, and the helix H2 is shown
in pink. Blue and pink shaded regions on AZIN1 represent the residues interacting with H1 and H2 regions of OAZ1 with the same color. (B) Identity of residues in site A of
AZIN1 is shown as blue colored sticks interacting with the blue colored helical region H1of OAZ1. (C) Amino acid residues in site B of AZIN1 is shown as pink-colored
sticks interacting with the pink colored helical region H2 of OAZ1.
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interact with the helical region H2 (shown in pink) of
OAZ1, including the N-terminal α-helix (residues
152–165) and residues D99, T123, and D124. Residues
in site B collectively form the Antizyme-Binding Element
(AZBE). Furthermore, Site-A in AZIN1 harbors important
residues that interact with the helical region H1 (shown in
blue) of OAZ1. Residues in site-A includes F170, Y321,
A325, S329, L328, D359, E360, L361, H390, S393, F395,
N396, and D397. The helical region H1 in OAZ1 includes
the c-terminal α-helix (residues 178–192) and the adjoin
ing loop (residues193-200) in OAZ1.
Interestingly AZIN1-OAZ1 interaction (Kd = 20 nM) is
10-fold stronger than ODC-OAZ1 interaction (Kd = 200
nM).49,50 Mutational studies suggest that the differences in
specific amino acid residues in the Antizyme-Binding
Element (AZBE) of ODC and AZIN1 may contribute
towards differential OAZ-binding affinities.49 Notably,
the corresponding mutations K125N and K140M in
AZIN1 decrease its binding to OAZ1 by 10-fold.
Conversely, mutating N125 and M140 in ODC to lysine
residues markedly increases ODC’s binding towards
OAZ1. However, it is unclear as to whether these residues
contribute to the increased affinity of AZIN1-OAZ1 inter
action. Biochemical studies on truncated OAZ1 variants
reveal that residues from 95–228 are sufficient for optimal
AZIN1 binding.51
Structural comparison of AZIN1-OAZ1 and ODCOAZ1 complexes reveal that amino acid residues A325
and S329 in AZIN1 are conserved in vertebrates. N327
and Y331 substitute these residues in ODC.48 Ghalali et al.
in a recent study demonstrated that ODC mutations
N327A and Y331S displayed increased binding affinity
(Kd = 192 nM and 277 nM respectively) towards OAZ1.
This suggests that these two residues may likely play a key
role in the decreased binding affinity of ODC-OAZ1 inter
action. Furthermore, Ghalali et al. performed an alanine
scanning mutagenesis experiment on AZIN1 wherein 39
alanine point mutations were introduced on the protein,
and the effect on OAZ1 binding was evaluated.50 Results
from this experiment indicate that while no single residue
in AZIN1 contributes to OAZ1 binding, a combination of
small contributions from several single residues may likely
be responsible.50 Additionally, results from the experiment
indicate that individual mutations at site A of AZIN1
decrease OAZ1 binding (increased Kd from 20 nM for
WT to ~80 nM for F395A) by up to 4-fold. Contrarily,
individual mutations at site B of AZIN1 (AZBE) did not
decrease OAZ1 binding. This suggests that the AZBE site
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in AZIN1 may not necessarily contribute to the increased
affinity of AZIN1-OAZ1 interaction. More importantly,
biophysical and structural characterization of AZIN1 inter
actions with other OAZ isoforms is not yet reported.

AZIN2 Interaction with OAZ Isoforms
The Human AZIN2 isoform shares 49% sequence identity
with human ODC. Not surprisingly, AZIN2 lacks ornithine
decarboxylase activity, likely due to its inability to bind
PLP.52,53 However, AZIN2 binds efficiently to three OAZ
isoforms (OAZ1, OAZ2, and OAZ3), thereby inhibiting
OAZ-mediated degradation of ODC.36,53 Although bio
chemical interactions of AZIN2 with OAZ isoforms have
not been quantitated at the protein level, the magnitude of
interaction has been compared with AZIN1 in mammalian
cell lines. Interestingly, AZIN2 binds less efficiently to
both OAZ1 and OAZ3 than AZIN1.43 Notably, investiga
tions on the molecular basis of AZIN2 interaction with
three OAZ isoforms via mutational analysis indicate that
amino acid residues in the antizyme-binding element
(AZBE) are essential for AZIN2-OAZ binding.44
To date, no structural studies on AZIN2-OAZ1 inter
action have been reported, except for an AZIN2 homology
model.44 While AZIN2 shares only 42% sequence identity
with AZIN1, the AZBE in AZIN2 is 62% identical to the
AZBE in AZIN1 (). A quick analysis of the sequence
alignments of AZIN1, AZIN2, and ODC reveal differences
in amino acid residues that could explain the differential
binding of these proteins to OAZ1. AZIN2 has six differ
ent amino acid substitutions, three of which happen to be
in the Antizyme Binding Element region of the protein.
Residues N93, S118, and K140 in AZIN1 are replaced by
A94, A119, and A141 in AZIN2. Additionally, residues
A325, S329, E360, H390, and D397 in AZIN1 are sub
stituted by the following residues, N328, F332, G363,
G393, and G400 in AZIN2. These are notable substitutions
as these residues in AZIN1 interact with residues in the H1
and H2 regions of OAZ1. Particularly, H390 and D397 in
AZIN1 make ionic interactions with E196 and R199 from
the loop next to the H2 helical region in OAZ. Both ODC
and AZIN2 likely lack these interactions due to alanine
substitutions at these sites. Additionally, like ODC, resi
dues N328 and F332 in AZIN2 may likely contribute to
a decreased binding towards OAZ1 compared to AZIN1.
Therefore, to further understand the functional features of
AZIN2, it is imperative to elucidate the biophysical and
structural aspects of AZIN2 binding to individual OAZ
isoforms.
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Figure 3 Sequence Alignment of AZIN1, AZIN2, and ODC. The figure shows a sequence alignment with site A residues of AZIN1 in blue-shaded regions. Residues that are
shown as red-colored letters are the ones that are different from the corresponding residues in AZIN1. The symbol (*) refers to identical, and the symbols (: and .) refer to
similar residues among these three proteins.

Physiological Role of Antizyme
Inhibitors
Physiological Role of AZIN1
Early reports on the in vivo role of AZIN1 suggest that the
Azin1 gene is essential for the survival of Azin1 knockout
transgenic mice.54 Decreased polyamine levels found in
transgenic mice reinforce the fact that AZIN1 is a positive
driver of intracellular polyamine levels. Moreover,
increased AZIN1 expression is correlated to elevated poly
amine levels leading to increased cell proliferation.29,55
Notably, different roles of AZIN1 in polyamine indepen
dent pathways are also reported. AZIN1 plays an active
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role in cell proliferation by preventing cyclin D1 degrada
tion, thereby improving the half-life of cyclin D1.56
However, structural details of AZIN1 interaction with
cyclin D1 are not clear. The subcellular localization of
AZIN1 changes at various phases of the cell cycle.55
AZIN1 expression increases during the early cell cycle at
G1 and G2/M phases.57 Also, AZIN1 colocalizes with
OAZ1 at centrosomes during the period from prophase to
late anaphase. Interestingly, AZIN1 colocalization with
OAZ1 was not observed during interphase, when ODC
activity increased.55,57 AZIN1 is believed to stabilize
ODC activity during interphase. However, the stabilization
mechanism is not clear.
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Figure 4 Protein Interactome of AZINs. (A) AZIN1 interactome showing 18 different proteins from three different databases. Only protein interactors with experimental
data are shown here. The letters B, S, and I correspond to BioGRID, STRING, and IntAct databases. (B) AZIN2 interactome showing 12 different proteins from three
different databases.

AZIN1 expression pattern has been correlated to genes
involved in the rat oestrous cycle and avian ovarian follicles,
suggesting a possible role of AZIN1 in reproductive
physiology.58,59 Additionally, AZIN1 is highly expressed in
vasopressinergic and oxytocinergic neurons of the male rat
hypothalamus. AZIN expression in hypothalamic nuclei is
directly correlated to increased polyamines resulting in tran
scriptional regulation of the neuropeptide hormone arginine
vasopressin.60 Furthermore, transcriptomic studies reveal that
glucocorticoids consistently upregulate the Azin1 gene in
brain cells.61

Physiological Role of AZIN2
Although AZIN2 expression stimulates ODC activity
and polyamine uptake, not much is known about its
effects on polyamine levels in vivo.36,52 Contrary to
Azin1 knockout mice, transgenic mice with deleted
Azin2 gene were found to be viable.54 AZIN2 is widely
expressed in differentiated cells. However, it does not
seem to be involved in cell proliferation, unlike
AZIN1.62 Specifically, AZIN2 is expressed in neuronal
cells of the frontal cortex and co-localizes with
N-methyl-d-aspartate (NMDA) glutamate receptor, sug
gesting a possible role in the central nervous system.63

OncoTargets and Therapy 2021:14

AZIN2 is highly expressed in the testes of adult
humans and mice, suggesting a possible role in
spermiogenesis.64 Strikingly, the spatial and temporal
expression pattern of AZIN2 is similar to OAZ3, the
testes-specific OAZ.27 However, unlike Oaz3 knockout
mice, Azin2 knockout mice are fertile and exhibit
decreased polyamine levels.63,65,66 Interestingly, OAZ3
interacts with testicular proteins that are unrelated to
polyamine metabolism.67,68 Given the correlation in the
expression patterns of AZIN2 and OAZ3, it is plausible
that AZIN2 may regulate OAZ3-mediated polyamine
independent pathways. A recent study showed decreased
testosterone levels in plasma and testis and decreased
sperm motility in Azin2 knockout mice, suggesting
a possible role of AZIN2 in testes physiology and repro
ductive biology.66
Furthermore, AZIN2 is expressed in the pancreas and
adrenal glands, suggesting a possible role in secretory
processes.62 AZIN2 also localizes to post-Golgi vesicles of
the secretory pathway and regulates intracellular vesicle
transport.69 Recent studies show that AZIN2 is expressed in
serotonin containing mast cell granules, thereby demonstrat
ing AZIN2 as a regulator of biogenic amines like serotonin
and histamines.70,71
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Antizyme Inhibitors in Mammalian
Disease
Role of AZIN1 in Cancers
AZIN1 is overexpressed in different types of human
malignancies, including gastric, lung, prostate, liver, and
ovarian cancers.72–75 Specifically, AZIN1 overexpressing
NIH3T3 fibroblast cells proliferated much faster than con
trol cells and generated tumors when injected into nude
mice.35 RAS transformed cell lines had increased AZIN1
expression and were more sensitive to increased polya
mine uptake. Additionally, silencing AZIN1 expression in
A549 lung cancer cells decreased polyamine levels and
reduced cell proliferation due to increased OAZ1 mediated
ODC degradation.76 More importantly, shRNA mediated
knockdown of Azin1 in both human and rat prostate cancer
diminished tumor volume in vivo following subcutaneous
injection into nude mice.77 These studies demonstrate the
therapeutic potential of AZIN1 in multiple cancers.
Recent studies reveal that the Azin1 transcript undergoes
mRNA editing in certain cancers, including hepatocellular
carcinoma (HCC), esophageal squamous cell carcinoma,
Non-Small Cell Lung Cancer (NSCLC), colorectal cancers,
and prostate cancers. mRNA editing involves the conver
sion of Adenosine to Inosine in primary mRNA transcripts,
a reaction catalyzed by the enzyme Adenosine Deaminases
Acting on RNA (ADAR), leading to diversification of the
transcriptome in human cells.78 mRNA editing of the Azin1
transcript, a target of ADAR, leads to a “gain-of-function”
phenotype. This phenotype leads to the substitution of ser
ine residue to glycine (S367G) on the translated protein.79
Such a phenotype was shown to augment tumor-initiating
potential leading to a more aggressive tumor behavior in
HCC and esophageal squamous cell carcinoma.79,80 mRNA
editing of Azin1 and subsequent translation of the mutant
AZIN1 protein was also observed in NSCLC patient
samples.81 In these NSCLC samples, AZIN1 protein
expression was higher in tumors with edited Azin1 than in
those with the non-edited transcript. In parallel, edited
AZIN1 at the protein level induced proliferation, invasion,
and migration of lung cancer cell lines.81 Furthermore,
analysis of tissue samples from multiple independent color
ectal cancer patient cohorts revealed Azin1 mRNA as one of
the most frequently edited transcripts.82 Additionally, these
edited transcripts enhanced the invasive potential of cancerassociated fibroblasts within the tumor microenvironment
in the colon.83 Specifically, edited Azin1 enhances spheroid
formation, with a corresponding increase in stemness
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markers in colorectal cancers.82 A recent study unveiled
a correlation between Azin1 mRNA editing levels and
lymph node metastasis in gastric cancer patients, thereby
demonstrating the potential of measuring Azin1 mRNA
editing status as a promising prognostic biomarker for this
cancer type.84 Another recent study analyzed the expression
and localization of AZIN1 in prostate cancer specimens and
demonstrated that nuclear localization of the mRNA-edited
AZIN1 protein is associated with a decreased survival
rate.85 mRNA-edited Azin1 transcripts are thought to
express a mutant protein localized in the cell nucleus with
an increased binding affinity towards OAZ1. However,
recombinantly expressed S367G mutant did not display
any increased affinity towards OAZ1, suggesting that
nuclear localization of the mutant AZIN1 may contribute
to oncogenesis via mechanisms independent of AZIN1OAZ1 interactions.50,85
AZIN1 plays a major role in modulating cell prolifera
tion and oncogenesis via polyamine independent mechan
isms. Notably, AZIN1 regulates Cyclin D1 (CCND1)
levels by preventing its degradation. CCND1 serves as
an active switch in regulating cell-cycle progression
through its association with Cyclin-Dependent Kinases
(CDKs). Normal cell-cycle progression involves constant
degradation of CCND1. Dysregulation of CCND1 activity
by preventing its degradation can lead to aberrant cell
proliferation in various cancer types.86,87 In this regard,
Azin1 silencing leads to diminished CCND1 levels result
ing in reduced cell proliferation.56 Interestingly, OAZ1
was shown to prevent cell cycle progression by binding
to and targeting CCND1 for proteasomal degradation.88
Strikingly, OAZ1 binds to CCND1 with Kd of 810 nM, 40
fold higher than its interaction with AZIN1 (Kd = 20
nM).89 AZIN1 overexpression can thus lead to OAZsequestration, thereby preventing CCND1degradation.
AZIN1 also contributes to cancer progression by neutra
lizing the tumor-suppressor functions of OAZ1 in polyamine
independent pathways. Notably, OAZ1 is a potent tumor
suppressor, the expression of which can prevent cell growth
and tumorigenesis.29,90 For example, OAZ1 expression
levels are downregulated in cisplatin-resistant Non-Small
Cell Lung Cancer Cells (NSCLC), thereby attributing
a major role in drug-resistant cancers.91 OAZ1 also mediates
the proteasomal degradation of DNP73 in a c-Jun dependent
manner.92 The anti-apoptotic DNP73 is a trans-activation
deficient isoform of P73, which is elevated in multiple
cancers.92–94 Interestingly, co-expression of AZIN1 with
either DNP73 or c-Jun prevented OAZ-mediated degradation
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of DNP73, suggesting a possible role of AZIN1 as a tumorproliferator. Additionally, the OAZ1/AZIN1 system is impli
cated to play a role in centrosome amplification.95
Centrosome amplification is a common feature of numerous
solid tumors and is an early event in tumorigenesis.96 While
OAZ1 overexpression reduces numerical centrosome
abnormalities, depletion of OAZ1 leads to centrosome
overamplification.95 Contrarily, AZIN1 overexpression
leads to centrosome overamplification, whereas silencing
the Azin1 gene decreases numerical centrosome
abnormalities.95 Interestingly, OAZ1 also mediates degrada
tion of other proteins associated with cell-cycle progression,
including SMAD1,97 AuroraA,98 MPs I,99 and loricrin.100
Therefore, AZIN1-mediated sequestering of OAZ may likely
regulate proteasomal degradation of these proteins, thereby
controlling cell-cycle progression.

Role of AZIN2 in Cancers
AZIN2 is mainly expressed in terminally differentiated cells,
such as neural cells,63 Leydig cells,101 and mast cells.70
Elevated expression of AZIN2 is observed in Purkinje cells
and the hippocampus of brains affected by Alzheimer’s
disease.63 However, the pathological relevance of this obser
vation is not clear. Although AZIN2 stimulates ODC activity
and polyamine uptake, it is not involved in cell proliferation
and is not found to be upregulated in many cancer types.
Strikingly, a recent study identified elevated expression of
AZIN2 in colorectal cancer (CRC) samples from a cohort of
840 patients.102 Immunohistochemical staining of CRC sam
ples revealed strong AZIN2 expression in invasive cells of
the tumor front. Also, they displayed morphological features
of epithelial-mesenchymal transition (EMT). Additionally,
AZIN2 overexpression in T84 CRC cells induced the accu
mulation of cell-derived CD63+ exosomes in the culture
medium, indicating a secretory phenotype.102 Notably,
CD63 expression is associated with advanced-stage CRC
with mucinous histology103 Taken together, these findings
attribute a pathological role for AZIN2 in CRC progression.

Cellular Protein-Interactome of
Antizyme Inhibitors
Besides polyamine homeostasis, AZINs are thought to
function in various cellular processes. While some AZINregulated cellular processes are implicated in diseases such
as cancers, most AZIN-mediated functions are unknown.
A likely reason is the lack of information about the cellular
protein interactome of AZINs. To date, no study has
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focused exclusively on identifying AZIN-interacting pro
tein networks in tissue-specific cell lines. To bridge this
gap, the current review will examine the identities of
AZIN-interacting proteins from three different databases.

Protein Interaction Network of AZIN1
The AZIN1 protein-interaction network is obtained from
three-different databases – STRING,104 BioGRID,105 and
IntAct.106 All three databases provide information regard
ing AZIN1 interactors based on predicted and experimen
tal evidence. To avoid algorithmic discrepancies among
these databases, only AZIN1 interactors with experimental
evidence is examined. A total of 18 different proteins are
identified as AZIN1 interactors with eight proteins found
exclusively on BioGRID, whereas only four proteins are
found to be common to all three databases (Figure 4A and
Table 1). Experimental evidence comes mainly from two
experimental techniques, High-throughput Affinity
Capture Mass Spectrometry and Yeast-two Hybrid metho
dology employed in various studies to identify tissue, and
cell line-specific global proteome-wide interaction
networks.
Interestingly, of the 18 protein interactors, 15 are unre
lated to polyamine-dependent pathways. Five different
studies utilized the Yeast-two Hybrid methodology to
identify proteome-wide interaction networks. Of these,
eight different proteins were identified as AZIN1 interac
tors. ABCC2, ADSSL1, ARNTL, and KHDRBS1 were
identified as AZIN1 interactors in a comprehensive study
to map the human liver protein interaction network using
yeast two-hybrid methodology.107 The functional rele
vance of these interactions is unclear. However, It is
worth noting that increased expression of ABCC2
(MRP2)108,109 and KHDRBS1 (Sam68)110,111 is associated
with multiple cancers.
A systematic study on acute lymphoblastic leukemia can
cer gene products revealed CDKN2A as a gene set with 29
distinct mutations from 1545 patient samples examined.112
A closer look at the functional associations between ALLgene products and their partners in the human proteome using
yeast two-hybrid detection assay revealed Azin1 as an inter
actor of CDKN2A.112 The CDKN2A gene encodes two tumorsuppressor proteins p16 and p14ARF, both involved in cell
cycle regulation.113 Notably, the downregulation of CDKN2A
is common in multiple cancers due to somatic mutations.
Therefore, it would be interesting to examine whether
AZIN1 interaction with CDKN2A might contribute to the
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Table 1 AZIN1-Interacting Proteins and Their Description
Protein

Description

Uniprot ID

Ref

ABCC2

Canalicular multi-specific organic anion transporter 1

Q92887

[107]

ADSSL1

Adenylosuccinate synthetase isozyme 1

Q8N142

[107]

ARNTL

Aryl hydrocarbon receptor nuclear translocator-like protein 1

O00327

[120]

CDKN2A

Cyclin-dependent kinase inhibitor 2A

P42771

[112]

ELAVL1

ELAV-like protein 1-A

Q1JQ73

[123]

FANCA

Fanconi anemia group A protein

O15360

[114]

FANCC

Fanconi anemia group C protein

Q00597

[114]

KHDRBS1

KH domain-containing, RNA-binding, signal transduction-associated protein 1

Q07666

[107]

KIF5B

Kinesin-1 heavy chain

P33176

[115,116]

KIF5C

Kinesin heavy chain isoform 5C

O60282

[115,116]

KLC1

Kinesin light chain 1

Q07866

[115,116]

KLC2

Kinesin light chain 2

Q9H0B6

[115,116]

KLC4

Kinesin light chain 4

Q9NSK0

[115,116]

MSRB3

Methionine-R-sulfoxide reductase B3

Q8IXL7

[115]

OAZ1

Ornithine decarboxylase antizyme 1

P54368

[115,116]

OAZ2

Ornithine decarboxylase antizyme 2

O08608

[115,118]

OAZ3

Ornithine decarboxylase antizyme 3

Q9R109

[116,119]

TDP2

Tyrosyl-DNA phosphodiesterase 2

O95551

[115,116]

AZIN1 function (at protein level) in cell-cycle regulation via
preventing CCND1 degradation.
Another yeast two-hybrid screen identified AZIN1 as
a potential interactor of Fanconi Anemia complementation
group A (FANCA) and group C (FANC) proteins from a list
of 69 proteins belonging to various cellular pathways.114
This study provided evidence for Fanconi Anemia proteins’
involvement in several pathways linked to the clinical phe
notype. However, it did not examine the role of AZIN1FANCA/FANC interactions in Fanconi Anemia.114
Exploring of the human protein interactome using
high-throughput affinity-purification mass spectrometry
in HEK292T cells identified 10 different protein inter
actors of AZIN1 from three separate studies. Not surpris
ingly, the three different OAZ isoforms, OAZ1,43,115–117
OAZ2,115,116,118 and OAZ3,116,119,120 were identified as
AZIN1 interactors. These studies also revealed the inter
action of AZIN1 with selective heavy chain (KIF5B,
KIF5C) and light chain (KLC1, KLC2, and KLC4)
Kinesin isoforms.115,116 Both KIF5B and KIF5C
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isoforms are expressed due to gene duplication of the
Kinesis heavy chain 5 (KIF5) gene belonging to the
kinesin 1 family.121 KIF5 protein is a tetramer compris
ing two heavy chains and two light chains and exhibits
motor activity to transport various cargo along microtu
bules. On the other hand, KLCs (KLC1-3) associates
with KIF5 through an N-terminal domain and are
involved in binding various cargos such as vesicles and
Golgi complexes.121 Furthermore, Kif5b knockdown in
mitotic cells results in centrosome amplification and
chromosomal segregation defect, suggesting a crucial
role for KIF5B in meiotic cell development and mitotic
cell division.122 Given these observations, AZIN1 might
play a likely role in centrosome regulation via kinesin
interaction. However, there is no evidence for the phy
siological relevance of AZIN1-Kinesin interaction, and it
remains to be seen as to whether such an interaction has
relevance in pathological cell lines.
High-throughput affinity-purification mass spectrome
try experiments in HEK292T cells also revealed the
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interaction of AZIN1 with two different enzymes, MSRB3
and TDP2.115,116 While MSRB3 decreases oxidative stress
by catalyzing the reduction of methionine sulfoxide in
proteins, TDP2 functions as a DNA repair enzyme. The
functional relevance of AZIN1 association with these
enzymes remains to be determined. AZIN1 also interreacts
with ELAV1 (Human antigen R), an RNA-binding protein
that binds and stabilizes mRNA to regulate gene
expression.123 The functional consequence of AZIN1ELAV1 interaction has not yet been explored.

Protein Interaction Network of AZIN2
Given the experimental evidence, AZIN2 interacts with 12
different proteins, of which 9 of them are common to
BioGRID105 and IntAct,106 whereas only 2 are common to
all three databases. Although the STRING104 database lists
10 unique AZIN2 interactors, 8 lack experimental evidence
and is purely based on text mining (Figure 4B). AZIN2
Interactors with experimental evidence are listed in Table 2.
AZIN2 was shown to interact with OAZ1,116 and
OAZ2,116 from a study that explored human interactome
using high-throughput affinity-purification mass spectro
metry. Additionally, AZIN2 interaction with OAZ3119,120
was established from two different yeast two-hybrid
screens. Although there is precedent in the literature (as
discussed above) for the physiological basis of AZIN2OAZ interactions, their structural and biophysical aspects
remain unclear.

In addition to OAZ1 and OAZ2, seven other protein
interactors of AZIN2 are identified from the highthroughput affinity-purification mass spectrometry study
(Table 2).116 AZIN2 interacts with CORO7, a ubiquitous
mammalian protein involved in maintaining Golgi struc
ture and function.124 Interestingly, AZIN2 localizes in the
ER-Golgi intermediate compartment and the cis-Golgi
network125 suggesting a likely physiological relevance
for AZIN2-CORO7 interaction. AZIN2 also interacts
with DDX11 and SMARCAL1, two different proteins
involved in DNA replication and chromatin regulation.
DDX11 is a DNA-dependent ATPase and a helicase that
is involved in DNA replication and sister chromatid
cohesion.126 SMARCAL1, on the other hand, is
a mediator of nucleosome restructuring and chromatin
remodeling during gene regulation and DNA repair.127
Besides, AZIN2 also interacts with LRF1, a nuclear recep
tor protein that regulates chromosome segregation during
mitosis through its interaction with the Heterochromatin
protein 1-α.128 Although there is precedent for polyaminedependent chromatin regulation, the functional relevance
of AZIN2 interaction with DDX11, SMARCL1, or LRF1
is unclear.
SMG8 is a protein cofactor that interacts with SMG1
kinase and is involved in non-sense mediated mRNA decay
(NMD) pathway,129 a surveillance process that targets and
degrades defective mRNA containing premature translation
termination codons.130 Interestingly, polyamines are known

Table 2 AZIN2-Interacting Proteins and Their Description
Protein

Description

Uniprot ID

Ref

CORO7

Coronin-7

P57737

[116]

DDX11

ATP-dependent DNA helicase DDX11

Q96FC9

[116]

LRIF1

Ligand-dependent nuclear receptor-interacting factor 1

Q5T3J3

[116]

OAZ1

Ornithine decarboxylase antizyme 1

P54368

[116]

OAZ2

Ornithine decarboxylase antizyme 2

O08608

[116]

OAZ3

Ornithine decarboxylase antizyme 3

Q9R109

[119,120]

PRAME

Melanoma antigen preferentially expressed in tumors

P78395

[116]

PSMC5

26S proteasome regulatory subunit 8

P62195

[135]

SMARCAL1

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1

Q9NZC9

[116]

SMG8

Protein SMG8

Q8ND04

[116]

TLN1

Talin-1

Q9Y490

[135]

TPD52L1

Tumor protein D53

Q16890

[116]
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to modulate alternative splicing of SSAT pre-mRNA via the
NMD pathway.131 However, the role of AZIN2 in regulat
ing the NMD pathway via SMG8 interaction is unknown.
Strikingly, AZIN2 interacts with tumor-associated proteins
PRAME132 and TPD52L1,133,134 which are overexpressed
in a variety of malignancies including breast cancers.
Particularly, TPD52L1 is shown to function as a cell-cycle
regulator protein involved in the G2-M transition in breast
cancer cell lines.133,134 However, AZIN2 is shown to have
no involvement in cell cycle regulation.62 Therefore, the
functional relevance of AZIN2 interaction with PRAME
and TPD52L1 in the context of human malignancies
remains to be determined.
On a different note, a recent study demonstrated the
interaction of TLN-1 and PSMC5 with a long non-coding
splice variant RNA of AZIN2 (lncRNA-AZIN2-sv),
through RNA-pulldown and RNA-immunoprecipitation
experiments.135 This study was aimed to identify the role
of AZIN2-splice variant mRNA in cardiomyocyte regen
eration via endothelial activation and angiogenesis.135
Notably, Tln1, a cytoskeletal protein, was shown to reg
ulate integrin activity along with its involvement in cell
spreading and flattening during angiogenesis.136 AZIN2splice variant mRNA was further shown to promote ubi
quitin-dependent Tln1 degradation via 26S proteasome
subunit ATPase 5 (PSMC5), leading to decreased βintegrin expression, an essential factor for endothelial
development and vessel formation. Taken together,
AZIN2-sv plays an active role in angiogenesis via Tln1
downregulation, thereby blocking the miR-214/PTEN/Akt
pathway.135

Conclusions and Future
Perspectives
This review summarizes the recent efforts in understand
ing the multi-faceted role of AZIN isoforms in mammalian
pathophysiology and sheds light on the cellular interac
tome of both AZIN isoforms. In short, AZINs play
a crucial role in polyamine homeostasis via their interac
tion with OAZ isoforms and regulate polyamineindependent cellular processes through their interaction
with multiple proteins. Despite our understanding of
AZINs, many questions remain unanswered due to a lack
of structural and biophysical evidence, which forms the
backbone of protein-protein interactions. For example,
while the structural and biophysical basis of the AZIN1OAZ1 interaction is reported,48–51 no such information
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exists for AZIN1 interactions with OAZ2 or OAZ3 and
AZIN2 interactions with OAZ1, OAZ2, or OAZ3. Albeit
identifying novel protein interactors of AZIN isoforms
outside the polyamine pathway, their biochemical and
biophysical aspects remain unknown. Additionally, to
understand and correlate AZIN’s role in disease progres
sion, it is imperative to identify AZIN interactors at the
protein level in various pathogenic states.
AZIN1 is upregulated in multiple cancers and is
thought to drive cancer progression via dysregulation of
polyamine synthesis and cell-cycle control. Although
AZIN2 was originally thought to have no involvement in
cancer progression, a recent study demonstrated
otherwise.102 Given its role in cancers, therapeutic target
ing of AZIN1-OAZ1 interactions using small molecules,
peptides, or proteins, may prove to be a viable approach
for cancer treatment, provided it is validated
rigorously.50,77 The rationale for the preceding statement
can be provided in two ways. 1) Because of its tight
control over the polyamine biosynthetic pathway, AZIN1
regulates polyamine levels, thereby controlling cellproliferation by sequestering OAZ1. Although targeting
ODC using DFMO (an established ODC inhibitor) pre
vents intracellular polyamine synthesis, it does not prevent
polyamine uptake from tumor microenvironments. On the
contrary, inhibiting AZIN-OAZ1 interaction may likely
free OAZ1, resulting in ODC degradation and decreased
polyamine uptake. 2) AZIN1 also controls cell cycle pro
gression by preventing OAZ1-mediated degradation of
proteins associated with cell-cycle regulation. Therefore,
inhibiting AZIN1-OAZ1 interaction may likely prevent
AZIN1-mediated cell-proliferation.
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